New clinical trial into myelofibrosis at the Clinique de Genolier

The Clinique de Genolier is the first centre in Switzerland to launch a new clinical trial in the field of myelofibrosis.

The « Manifest-3 » trial, sponsored by Novartis and led by Dr Rebmann as Principal Investigator, aims to evaluate a new treatment option for patients with this condition. It aims to broaden treatment options in a context where medical needs remain significant.

This launch marks an important milestone in the development of clinical research within the Swiss Medical Network. It demonstrates the commitment of the teams at the Clinique de Genolier to advancing therapeutic approaches and actively contributing to medical progress.

Clinical research plays a vital role within our network. It enables us to offer innovative solutions within a structured framework, for the benefit of patients and healthcare professionals.

For further information: Research website